|
Summary
October 2007, Vol. 11, No. 10, Pages 1287-1298
, DOI 10.1517/14728222.11.10.1287
Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancerParaic A KennyLife Sciences Division, Lawrence Berkeley National Laboratory, 1 Cyclotron Road, MS977-225A, University of California, Berkeley, CA 94720, USA pakenny@lbl.gov TNF-α converting enzyme (TACE/ADAM17) is a transmembrane metalloprotease that plays a key role in the cleavage and mobilization of receptor ligands that are initially synthesized as membrane-tethered precursors. For many years, attention has focused on the role of TACE-dependent TNF-α cleavage in arthritis and, more recently, it has become apparent that TACE also plays an important role in regulating epidermal growth factor receptor activity in several tumor types. This review presents the background to these findings and a rationale for the continued development of TACE inhibitors for the treatment of epidermal growth factor receptor-dependent epithelial tumors. Forward Links to Citing ArticlesMark Katakowski, Feng Jiang, XuGuang Zheng, Jorge A. Gutierrez, Alexandra Szalad, Michael Chopp. (2009) Tumorigenicity of cortical astrocyte cell line induced by the protease ADAM17. Cancer Science Online publication date: 1-Jul-2009. CrossRef Brian W. Booth, Gilbert H. Smith. (2007) Roles of transforming growth factor-α in mammary development and disease. Growth Factors 25:4, 227-235 Online publication date: 1-Jan-2007. Summary | Full Text | PDF (199 KB) | PDF Plus (200 KB) |
|





TOC Alert